X4 Pharmaceuticals, Inc. (XFOR)
3.265
+0.02
(+0.46%)
USD |
NASDAQ |
Oct 27, 16:00
3.265
0.00 (0.00%)
After-Hours: 18:19
X4 Pharmaceuticals Enterprise Value : 181.05M for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 181.05M |
| October 23, 2026 | 180.09M |
| October 22, 2026 | 176.24M |
| October 21, 2026 | 157.98M |
| October 20, 2026 | 158.94M |
| October 19, 2026 | 132.99M |
| October 16, 2026 | 117.61M |
| October 15, 2026 | 122.42M |
| October 14, 2026 | 104.16M |
| October 13, 2026 | 118.57M |
| October 12, 2026 | 139.72M |
| October 09, 2026 | 148.37M |
| October 08, 2026 | 136.84M |
| October 07, 2026 | 138.76M |
| October 06, 2026 | 134.91M |
| October 05, 2026 | 147.41M |
| October 02, 2026 | 140.68M |
| October 01, 2026 | 140.68M |
| September 30, 2026 | 147.41M |
| September 29, 2026 | 147.41M |
| September 28, 2026 | 158.46M |
| September 25, 2026 | 157.98M |
| September 24, 2026 | 157.02M |
| September 23, 2026 | 167.59M |
| September 22, 2026 | 198.35M |
| Date | Value |
|---|---|
| September 21, 2026 | 204.60M |
| September 18, 2026 | 212.77M |
| September 17, 2026 | 205.08M |
| September 16, 2026 | 206.04M |
| September 15, 2026 | 216.61M |
| September 14, 2026 | 216.61M |
| September 11, 2026 | 205.08M |
| September 10, 2026 | 195.47M |
| September 09, 2026 | 214.69M |
| September 08, 2026 | 205.56M |
| September 04, 2026 | 256.98M |
| September 03, 2026 | 256.98M |
| September 02, 2026 | 256.98M |
| September 01, 2026 | 259.86M |
| August 31, 2026 | 256.98M |
| August 28, 2026 | 256.98M |
| August 27, 2026 | 275.24M |
| August 26, 2026 | 269.47M |
| August 25, 2026 | 268.51M |
| August 24, 2026 | 257.94M |
| August 21, 2026 | 256.98M |
| August 20, 2026 | 256.02M |
| August 19, 2026 | 268.51M |
| August 18, 2026 | 273.32M |
| August 17, 2026 | 281.97M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Sarepta Therapeutics, Inc. | 2.156B |
| Arrowhead Pharmaceuticals, Inc. | 8.099B |
| Oncolytics Biotech, Inc. | 55.31M |
| Sangamo Therapeutics, Inc. | 39.84M |
| Anixa Biosciences, Inc. | 86.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.16M |
| Revenue (Quarterly) | 8.806M |
| Total Expenses (Quarterly) | 24.96M |
| EPS Diluted (Quarterly) | -0.1279 |
| Gross Profit Margin (Quarterly) | 81.24% |
| Profit Margin (Quarterly) | -183.5% |
| Earnings Yield | -36.56% |
| Normalized Earnings Yield | -36.32 |